Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

  • STATUS
    Recruiting
  • End date
    Jun 25, 2022
  • participants needed
    152
  • sponsor
    European Organisation for Research and Treatment of Cancer - EORTC
Updated on 25 January 2021

Summary

Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs.

The study will include two cohorts of patients: Cohort A, which comprises chemo-nave patients, and Cohort B, which comprises pretreated patients.

Description

Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin + bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease progression. As long as Cohort A is open to recruitment, patients who will be treated by chemotherapy will be simultaneously enrolled in Cohort B. Accrual in Cohort B will be stopped when recruitment of 76 eligible patients in Cohort A is reached.

Details
Condition Oral Neoplasm, salivary gland cancer, Oral Cavity Cancer, Oral Cancer
Treatment bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
Clinical Study IdentifierNCT01969578
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer; adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells based on central review
Sufficient tissue must be available either historically or a biopsy must be done as a part of this study and sent to central review for patients enrolled in both cohorts
Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according to RECIST criteria version 1.1 (target lesion)
Patients older than 18 years old
Performance Status ECOG 0-1
Adequate bone marrow function
WBC 3.5/10exp9L
absolute neutrophil count 1,5x10exp9/L
hemoglobin > 9 g/dL
platelet count 100x10exp9/L
Adequate liver function
AST < 2.5 times upper limit of normal
ALT < 2.5 times upper limit of normal
bilirubin < 1.5 times upper limit of normal
the concomitant evidence of AST < 2.5 times upper limit of normal, ALT < 2.5 times upper limit of normal and bilirubin > 1.5 times upper limit of normal is not allowed
Adequate renal function
serum creatinine level ( 1.3 mg/dL)
calculated creatinine clearance 60 mL/min based on the standard Cockcroft and Gault formula
Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG; additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac function should be demonstrated by a left ventricular ejection fraction (LVEF) 50% (within 2 weeks prior to treatment start)

Exclusion Criteria

Actively bleeding tumor if the patient is intended to be treated with carboplatin
Patients with bone disease or brain disease as the sole disease site; brain metastases are allowed in case of systemic disease, but must have been treated at least 4 weeks before enrollment and must be stable after that
recent history of congestive heart failure, unstable angina within the past 3 months, cardiac arrhythmia, myocardial infarction, congenital long QTc prolongation, stroke, TIA within the past 6 months
previous cardiac toxicity induced by another anthracycline or previous exposure to maximum cumulative dose of another anthracycline if the patient is intended to be treated with doxorubicin
history of allergic reactions attributed to compounds of similar chemical or biological composition to cis/carboplatin, paclitaxel, doxorubicin, bicalutamide or triptorelin
concomitant medications with terfenadine, astemizole, cisaprid
use of phenytoin
Patients who received vaccine for yellow fever
active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix
positive serum pregnancy test within 1 week prior to the first dose of study treatment for Women of child bearing potential (WOCBP)
no adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment for patients of childbearing / reproductive potential
psychological, familiar, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
written informed consent not given according to ICH/GCP, and national/local regulations, before patient registration
participation in another interventional clinical trial in the preceding 4 weeks prior to randomization
for cohort A patients: previous chemotherapy for recurrent/metastatic disease (previous chemotherapy given concomitantly with RT in the past is allowed, including cisplatin but it should be completed at least 6 months before enrollment)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note